LSA
ALNY icon

Leonteq Securities AG’s Alnylam Pharmaceuticals ALNY Stock Holding History

Leonteq Securities AG’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$84.8K – 1245
2021
Q4 		$84.8K Buy
+500
New +$92.9K ﹤0.01% 805

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Leonteq Securities AG's ALNY Position: Q2 2026 in Review

Leonteq Securities AG increased its Alnylam Pharmaceuticals (ALNY) stake by 95% in Q2 2026, buying an estimated $71.2K and bringing the position to 484 shares worth $146K. The position accounts for 0.01% of the portfolio, ranked #627.

Leonteq Securities AG first reported a position in ALNY in Q4 2020 and has held it in 22 quarters since. The position peaked at $412K in Q1 2021. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Leonteq Securities AG held 484 shares of Alnylam Pharmaceuticals worth $146K as of Q2 2026.
  • Leonteq Securities AG bought 236 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $71.2K.
  • Alnylam Pharmaceuticals made up 0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #627 holding.
  • Leonteq Securities AG first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Leonteq Securities AG's Alnylam Pharmaceuticals position peaked at $412K in Q1 2021.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.